Filing Flows › Prokidney (PROK) › R&D spending
Prokidney (PROK) R&D spending by quarter
Prokidney's R&D spending was $36.1M in Q2 2026 (second quarter 2026), +7% from Q1 2026. Over the last 7 quarters it ranged from $25.9M (Q2 2025) to $39.8M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $36.1M | +7% | +39% |
| Q1 2026 | $33.8M | -0.9% | +24% |
| Q4 2025 | $34.2M | +27% | -14% |
| Q3 2025 | $26.8M | +4% | — |
| Q2 2025 | $25.9M | -5% | — |
| Q1 2025 | $27.3M | -31% | — |
| Q4 2024 | $39.8M | — | — |
Q2 2026 at a glance
Prokidney, Q2 2026: revenue $150K (-32% year over year), net loss $46.4M, operating cash flow −$40.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Prokidney's R&D spending?
Prokidney's R&D spending was $36.1M in Q2 2026 (second quarter 2026), +7% from Q1 2026.
How has Prokidney's R&D spending changed?
Over the last 7 quarters it ranged from $25.9M (Q2 2025) to $39.8M (Q4 2024).